NO more muscle fatigue
Open Access
- 2 March 2009
- journal article
- editorial
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 119 (3) , 448-450
Abstract
NOS is a key enzyme in the production of NO, a molecule that directly regulates vasorelaxation and blood supply. Diverse forms of muscle disease have been clinically associated with unusual fatigue after exercise. The localization of neuronal NOS (nNOS) at the plasma membrane of muscle has recently been shown to prevent muscle fatigue after exercise. In this issue of the JCI, Lai et al. show that dystrophin — the structural protein missing in individuals with Duchenne muscular dystrophy — anchors nNOS to the sarcolemma through a direct interaction with dystrophin spectrin-like repeats 16 and 17 (see the related article beginning on page 624). Furthermore, in another recently reported study of mouse models of muscular dystrophy, phosphodiesterase 5A inhibitors were used to treat the downstream ischemia that is associated with nNOS mislocalization. Collectively, these findings significantly advance our understanding of exercise-induced muscle fatigue and its role in muscle disease.Keywords
This publication has 21 references indexed in Scilit:
- Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophyJournal of Clinical Investigation, 2009
- Sarcolemma-localized nNOS is required to maintain activity after mild exerciseNature, 2008
- Functional Deficits in nNOSμ-Deficient Skeletal Muscle: Myopathy in nNOS Knockout MicePLOS ONE, 2008
- Akt activation prevents the force drop induced by eccentric contractions in dystrophin-deficient skeletal muscleHuman Molecular Genetics, 2008
- Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiencyProceedings of the National Academy of Sciences, 2008
- Functional capacity of dystrophins carrying deletions in the N-terminal actin-binding domainHuman Molecular Genetics, 2007
- Challenges and opportunities in dystrophin-deficient cardiomyopathy gene therapyHuman Molecular Genetics, 2006
- Exercise therapy in patients with myopathyCurrent Opinion in Neurology, 2000
- Role for α-dystrobrevin in the pathogenesis of dystrophin-dependent muscular dystrophiesNature Cell Biology, 1999
- Impaired metabolic modulation of α-adrenergic vasoconstriction in dystrophin-deficient skeletal muscleProceedings of the National Academy of Sciences, 1998